ESTRO 2025 - Abstract Book

S1536

Clinical – Mixed sites & palliation

ESTRO 2025

Conclusion: Oligometastatic renal cell and prostate cancers were associated with prolonged STFS after SBRT. Histology-specific randomized trials comparing SBRT alone with STx alone or in combination are warranted to determine the influence on survival and quality of life.

Keywords: SBRT, oligometastatic disease, systemic therapy